CardioNova has become resident of the Skolkovo Innovative Center Biomedical Cluster

On December 19th, within the framework of the International Forum “Support for education, research and innovations in Skolkovo”, a regular grand ceremony for delivery of the resident status of the Skolkovo Innovative Center took place. At the Ceremony, a Russian biotech company CardioNova, one of portfolio companies of Maxwell Biotech Group, joined the Biomedical Cluster of the Skolkovo Innovative Center.

The goal of CardioNova is to develop and introduce to the Russian market innovative drugs aimed at preventive care and treatment of cardiovascular diseases. Not long ago CardioNova was invested by Maxwell Biotech Venture Fund created with the participation of the RVC capital. CardioNova has become the 6th company of Maxwell Biotech Group that joined Skolkovo.

Cardiovascular diseases remain the biggest cause of deaths worldwide. One of the main factors for cardiovascular pathologies progression is dislipidemy (increase in cholesterin level) that results in vessel arterial sclerotic disease. As a result, the risk for such acute ischemic conditions as myocardial infarction, apoplectic attack, as well as limb ischemia, increases considerably. Experts forecast that by year 2020 a number of people, dying from cardiovascular diseases, will reach 25 million per year. In Russia, annually over 1 million people die from diseases related to vessel arterial sclerotic disease, and about 400 thousand become invalid. Thus, the prevalence rate of such disease type represents not only serious medical but social and economic problem as well.

The first drug of CardioNova is aimed at treatment of dislipidemy and preventive treatment of atherosclerosis. The designed formula (AHRO-001) represents a low-molecular substance of C24 cholic acid family. Thanks to its physic-chemical parameters, the anticipated drug will be able to reduce significantly the cholesterin level in blood, as well as potentially reduce the size of atherosclerosis plaques. The first drug of CardioNova aimed at treatment of dislipidemy and preventive treatment of atherosclerosis is being developed in close cooperation with an American public biotech company AtheroNova, Inс (OTC: AHRO).


Anna Zelenkova,
PR director with Maxwell Biotech Group;
Tel.: +7 (495) 411-6992
E-mail: zelenkova@maxwellbiotech.ru

Search form